An exception is a case by Gou et al., who described an ETV6::PDGFRB-positive patient with concurrent NPM1, TET2, and NOTCH3 mutations and 46,XY,del(12)(p13p11.2), who developed a PDGFR-translocation positive T-lymphoblastic lymphoma while on imatinib (10). Here, TET2 is linked to T-lymphoblastic lymphoma.